Author: Ken Dropiewski

Baxter Announces U.S. FDA Approval and Launch of Ready-to-use Cardiovascular Medicine Norepinephrine in Premix Formulation

First and only manufacturer-prepared premix formulation of norepinephrine available Offers variety of storage options under refrigeration and at room temperature, allowing drug to be placed closer to patient care settings Ready-to-use format means less chance of compounding errors and touch contamination associated with compounded drug formulations DEERFIELD, Ill.–(BUSINESS WIRE)–Baxter International […]

DiNAQOR Appoints Medical Device Leader Mark Dehdashtian to Oversee New U.S.-Based Division, Device Development and Production

ZURICH-SCHLIEREN, Switzerland and LAGUNA HILLS, Calif., Sept. 23, 2021 /PRNewswire/ — DiNAQOR, a genetic medicine platform company focused on addressing severe inherited cardiac diseases, today announced it has expanded its leadership team by appointing veteran medical device leader Mark Dehdashtian to serve as Executive Vice President, Medical Devices. As the company grows its U.S. footprint, Mr. Dehdashtian […]

Draupnir Bio establishes Scientific Advisory Board of European experts in cholesterol metabolism and cardiovascular disease

Draupnir Bio establishes Scientific Advisory Board of European experts in cholesterol metabolism and cardiovascular disease Copenhagen, Denmark, 23 September 2021 – Draupnir Bio (“Draupnir”), a biotechnology company developing small molecule modulators of PCSK9 to transform the treatment of heart disease, today announces the establishment of its scientific advisory board (SAB) comprising global leaders in carbohydrate chemistry, the regulation […]

Verve Therapeutics Reports New Preclinical Data with VERVE-101 Demonstrating Robust, Durable and Precise Editing of the PCSK9 Gene for the Treatment of Cardiovascular Disease

Treatment of Non-Human Primates with Clinical Candidate, VERVE-101, Led to Durable Reductions of PCSK9 Protein and Low-density Lipoprotein Cholesterol Comprehensive Off-Target Editing Analysis Using Industry Leading Methods, ONE-seq and Digenome-seq Showed No Off-Target Editing Across 244 Potential Sites in Human Liver Cells Data Support Continued Advancement of VERVE-101 Toward IND Submission […]

Renovacor Announces the Appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science

Dr. Shin to help advance REN-001 into the clinic by leveraging nearly two decades of expertise in clinical development, academic research and medical practice PHILADELPHIA–(BUSINESS WIRE)–Renovacor, Inc. (NYSE: RCOR), an early-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today […]

NeuroVasc Announces First Patient Enrolled in ENVI™-SR Mechanical Thrombectomy System Clinical Trial in China

Pivotal trial will assess use of the device for blood clot removal in strokes IRVINE, Calif.–(BUSINESS WIRE)–NeuroVasc Technologies, Inc. today announced that the first patient has been treated in a Chinese Pivotal Randomized Controlled Trial to evaluate the safety and efficacy of the ENVI™-SR Mechanical Thrombectomy System (ENVI™-SR), a stent-retriever for […]


– New enhancements to Abbott’s Epic valve – the most widely used mitral tissue heart valve in the U.S. and globally – can improve implantation and allow compatibility for future transcatheter valve procedures – Epic Plus designed to help patients with more complex cases of aortic or mitral regurgitation or […]

W. L. Gore & Associates Enhances GORE® VIABAHN® Endoprosthesis Portfolio With Lower Profile Delivery

Improvements to large diameter devices include accessibility through smaller sheaths while providing enhanced visualization by adding radiopaque markers 25 years of continued innovation PUTZBRUNN, Germany, Sept. 22, 2021 /PRNewswire/ — As part of efforts to continuously improve medical solutions for patients with complex vascular disease, W. L. Gore & Associates, Inc. (Gore) announced […]